(Q38041260)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22954349%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

title

A drug safety evaluation of everolimus in kidney transplantation (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22954349%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22954349%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

2

Karsten Midtvedt

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22954349%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

author name string

Hallvard Holdaas

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22954349%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

language of work or name

English

0 references

publication date

6 September 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22954349%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Drug Safety

12 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22954349%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

volume

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22954349%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22954349%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

page(s)

1013-1022

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22954349%20AND%20SRC:MED&resulttype=core&format=json

The natural history of chronic allograft nephropathy

12 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.722993

Chronic progressive calcineurin nephrotoxicity: an overstated concept

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.722993

Chronic calcineurin inhibitor nephrotoxicity-lest we forget

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.722993

Optimal immunosuppression to prevent chronic allograft dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.722993

Sotrastaurin, a novel small molecule inhibiting protein kinase C: first clinical results in renal-transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.722993

Costimulation blockade with belatacept in renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.722993

Everolimus and long-term outcomes in renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.722993

Molecular mechanisms of action of new xenobiotic immunosuppressive drugs: tacrolimus (FK506), sirolimus (rapamycin), mycophenolate mofetil and leflunomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.722993

SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.722993

Entry-into-human study with the novel immunosuppressant SDZ RAD in stable renal transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.722993

Sirolimus and everolimus intestinal absorption and interaction with calcineurin inhibitors: a differential effect between cyclosporine and tacrolimus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.722993

Comparison of the in vitro metabolism of the macrolide immunosuppressants sirolimus and RAD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.722993

Pharmacokinetics and tolerability of 40-0-[2-hydroxyethyl]rapamycin in de novo liver transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.722993

Influence of hepatic impairment on everolimus pharmacokinetics: implications for dose adjustment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.722993

Differential influence of two cyclosporine formulations on everolimus pharmacokinetics: a clinically relevant pharmacokinetic interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.722993

Everolimus exposure in cardiac transplant recipients is influenced by concomitant calcineurin inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.722993

Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.722993

Cyclosporine A- and tacrolimus-mediated inhibition of CYP3A4 and CYP3A5 in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.722993

Clinical development of an everolimus pediatric formulation: relative bioavailability, food effect, and steady-state pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.722993

Effect of food on everolimus absorption: quantification in healthy subjects and a confirmatory screening in patients with renal transplants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.722993

Interaction of sirolimus and everolimus with hepatic and intestinal organic anion-transporting polypeptide transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.722993

Interaction between everolimus and tacrolimus in renal transplant recipients: a pharmacokinetic controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.722993

Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.722993

Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multicenter, phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.722993

Everolimus (Certican) 12-month safety and efficacy versus mycophenolate mofetil in de novo renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.722993

Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.722993

Everolimus and reduced-exposure cyclosporine in de novo renal-transplant recipients: a three-year phase II, randomized, multicenter, open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.722993

Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.722993

Optimal everolimus concentration is associated with risk reduction for acute rejection in de novo renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.722993

Reduced exposure to calcineurin inhibitors in renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.722993

The ORION study: comparison of two sirolimus-based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.722993

Early, abrupt conversion of de novo renal transplant patients from cyclosporine to everolimus: results of a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.722993

Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.722993

Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.722993

Minimization of maintenance immunosuppression early after renal transplantation: an interim analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.722993

Conversion of long-term kidney transplant recipients from calcineurin inhibitor therapy to everolimus: a randomized, multicenter, 24-month study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.722993

Cancer incidence before and after kidney transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.722993

Cyclosporine induces cancer progression by a cell-autonomous mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.722993

Tacrolimus enhances transforming growth factor-beta1 expression and promotes tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.722993

Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.722993

mTOR, cancer and transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.722993

Pro- and anti-cancer effects of immunosuppressive agents used in organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.722993

Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.722993

Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.722993

Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.722993

Sirolimus for Kaposi's sarcoma in renal-transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.722993

Conversion to sirolimus: a successful treatment for posttransplantation Kaposi's sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.722993

Kaposi's sarcoma resolves after sirolimus therapy in a patient with pemphigus vulgaris

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.722993

Randomized controlled trial of sirolimus for renal transplant recipients at high risk for nonmelanoma skin cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.722993

Switch to a sirolimus-based immunosuppression in long-term renal transplant recipients: reduced rate of (pre-)malignancies and nonmelanoma skin cancer in a prospective, randomized, assessor-blinded, controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.722993

Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.722993

Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.722993

Everolimus for advanced pancreatic neuroendocrine tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.722993

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.722993

Infection in solid-organ transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.722993

The impact of cytomegalovirus infection and disease on rejection episodes in renal allograft recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.722993

Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.722993

A lower incidence of cytomegalovirus infection in de novo heart transplant recipients randomized to everolimus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.722993

The changing role of mTOR kinase in the maintenance of protein synthesis during human cytomegalovirus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.722993

Rapamycin-resistant mTORC1 kinase activity is required for herpesvirus replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.722993

Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.722993

Inhibition of polyomavirus BK-specific T-Cell responses by immunosuppressive drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.722993

Anti-BK virus mechanisms of sirolimus and leflunomide alone and in combination: toward a new therapy for BK virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.722993

Prevention of cardiovascular disease in adult recipients of kidney transplants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.722993

Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.722993

Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.722993

Mammalian target of rapamycin inhibitor dyslipidemia in kidney transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.722993

Effects of sirolimus on lipids in renal allograft recipients: an analysis using the Framingham risk model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.722993

Sirolimus is associated with new-onset diabetes in kidney transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.722993

Reduction of left ventricular mass by lisinopril and nifedipine in hypertensive renal transplant recipients: a prospective randomized double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.722993

Hypertrophic cardiomyopathy associated with tacrolimus in paediatric transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.722993

Inhibition of mTOR signaling with rapamycin regresses established cardiac hypertrophy induced by pressure overload

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.722993

Hyperhomocysteinemia in renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.722993

Homocysteine-lowering and cardiovascular disease outcomes in kidney transplant recipients: primary results from the Folic Acid for Vascular Outcome Reduction in Transplantation trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.722993

Lower homocysteine levels in renal transplant recipients treated with everolimus: a possible link with a decreased cardiovascular risk?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.722993

Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.722993

The role of mammalian target of rapamycin inhibitors in the treatment of advanced renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.722993

Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.722993

De novo everolimus-based therapy in renal transplant recipients: effect on proteinuria and renal prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.722993

Tubular toxicity in sirolimus- and cyclosporine-based transplant immunosuppression strategies: an ancillary study from a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.722993

Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.722993

mToR inhibitors-induced proteinuria: mechanisms, significance, and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.722993

Management of side effects of sirolimus therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.722993

Comparison of the effect of rapamycin and FK506 on release of prostacyclin and endothelin in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.722993

Cutaneous adverse events in renal transplant recipients receiving sirolimus-based therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.722993

A retrospective review of liver transplant patients treated with sirolimus from a single center: an analysis of sirolimus-related complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.722993

Gonadal impact of target of rapamycin inhibitors (sirolimus and everolimus) in male patients: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.722993

Sirolimus may reduce fertility in male renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.722993

Gonadal dysfunction and infertility in kidney transplant patients receiving sirolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.722993

Wound-healing complications after kidney transplantation: a prospective, randomized comparison of sirolimus and tacrolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.722993

Incidence of delayed graft function and wound healing complications after deceased-donor kidney transplantation is not affected by de novo everolimus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.722993

Wound complications following kidney and liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.722993

Comparison of sirolimus vs. mycophenolate mofetil on surgical complications and wound healing in adult kidney transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.722993

Are wound complications after a kidney transplant more common with modern immunosuppression?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.722993

Chronic renal failure after transplantation of a nonrenal organ

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.722993

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.722993

The podocyte as a direct target of immunosuppressive agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.722993

10.1517/14740338.2012.722993

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22954349%20AND%20SRC:MED&resulttype=core&format=json

release_ic7baq57fber7mmu3t52tdhbi4

12 February 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ic7baq57fber7mmu3t52tdhbi4

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference